MarketResearchReports.Biz
announces addition of new report"
Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug
Forecast and Market Analysis to 2024 "to
its database.
Congenital
Hemophilia A and B are bleeding disorders that are caused by genetic
X-linked deficiencies in the blood clotting Factors VIII and IX,
respectively. Hemophilia manifests as mild, moderate, or severe
inability to form clots, depending upon the endogenous levels of
circulating factor in an individual patient. The mainstay of
treatment for hemophilia is to replace the missing FVIII or FIX,
produced using plasma-derived or recombinant methods. Some patients
develop inhibitors to FVIII or FIX treatment and need a bypassing
agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or
B often require lifelong treatment to prevent and control bleeding
episodes, and this therefore represents a lucrative sales
opportunity.
The
total market for recombinant hemophilia treatment in the 5EU is
expected to grow from approximately $2.08 billion in 2014 to $2.36
billion in 2024. This growth will be driven by increasing rates of
recombinant factor replacement therapies across the 5EU countries; in
Italy and Spain in particular, where the current rate of prophylactic
treatment is relatively low, an increasing proportion of adult
patients are getting prophylactic treatments. GlobalData expects
moderate and high rates of adoption of the long-acting rFVIII and
rFIX therapies, respectively, over the forecast period. However,
GlobalDatas primary research indicates that the high annual cost of
therapy is of great concern among physicians and regulators in Europe
and therefore the opportunities for premium pricing for new therapies
will be limited during the forecast period.
View Report At
:http://www.marketresearchreports.biz/analysis/759745
Scope
- Overview of Hemophilia A and
B including epidemiology, etiology, symptoms, diagnosis, pathology
and treatment guidelines as well as an overview on the competitive
landscape.
- Detailed information on the
key drugs in 5EU including product description, safety and efficacy
profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in 5EU from 2014-2024.
- Analysis of the impact of key
events as well the drivers and restraints affecting 5EU Hemophilia A
and B market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for Hemophilia A
and B.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2014-2024 in 5EU.
Download Sample copy of this
Report at
Table of Contents
1.1
List of Tables
1.2
List of Figures
2
Introduction
2.1
Catalyst
2.2
Related Reports
2.3
Upcoming Related Reports
3
Disease Overview
3.1
Etiology and Pathophysiology
3.1.1
Etiology
3.1.2
Pathophysiology
3.1.3
Prognosis and Quality of Life
3.2
Symptoms
3.2.1
Hemophilia A and B
3.2.2
Inhibitors
4
Disease Management
4.1
Treatment Overview
4.1.1
Hemophilia A and B Diagnosis
4.1.2
Hemophilia A and B Treatment
4.1.3
Diagnosis of Inhibitors
4.1.4
Treatment of Inhibitors
4.2
France
4.2.1
Clinical Practice
4.3
Germany
4.3.1
Clinical Practice
4.4
Italy
4.4.1
Clinical Practice
4.5
Spain
4.5.1
Clinical Practice
4.6
UK
4.6.1
Clinical Practice
5
Competitive Assessment
5.1
Overview
5.2
Strategic Competitive Assessment
5.3
Product Profiles - Hemophilia A
5.3.1
Advate (Octocog Alfa)
5.3.2
Kogenate FS/Helixate FS (Octocog Alfa)
5.3.3
Xyntha/ReFacto AF (Moroctocog Alfa)
5.3.4
Recombinate (Octocog Alfa)
5.3.5
Eloctate (Efmoroctocog Alfa)
5.3.6
NovoEight (Turoctocog Alfa)
5.3.7
Nuwiq (Simoctocog Alfa)
5.4
Product Profiles - Hemophilia B
5.4.1
BeneFIX (Nonacog Alfa)
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment